Cargando…
Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients
INTRODUCTION: Side-effects are frequently encountered in classic chemotherapy. However, the recent development of targeted treatments has resulted in a diminution of these. The most common side-effects are dermatological. AIM: To investigate cutaneous changes occurring in patients using classic and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802962/ https://www.ncbi.nlm.nih.gov/pubmed/35126018 http://dx.doi.org/10.5114/ada.2020.99943 |
_version_ | 1784642776851283968 |
---|---|
author | Utlu, Zeynep Bilen, Handan |
author_facet | Utlu, Zeynep Bilen, Handan |
author_sort | Utlu, Zeynep |
collection | PubMed |
description | INTRODUCTION: Side-effects are frequently encountered in classic chemotherapy. However, the recent development of targeted treatments has resulted in a diminution of these. The most common side-effects are dermatological. AIM: To investigate cutaneous changes occurring in patients using classic and targeted chemotherapeutic agents, and the prevalence of these changes in the two groups. MATERIAL AND METHODS: One hundred twenty-eight volunteer oncological patients using chemotherapeutic agents were included in this prospective study. Two subgroups were established, patients using classic and those using targeted chemotherapeutic agents. RESULTS: Xerosis was the most common side-effect, being seen in 93 (72.7%) of the 128 patients. Other common side-effects included alopecia, pruritus, mucositis, skin pigmentation, and palmar-plantar erythema. The most common side-effects in the classic chemotherapeutic group were xerosis seen in 71 (75.5%) patients, pruritus in 50 (53.2%), alopecia in 49 (52.1%), and nail changes in 43 (45.7%). The most common side-effects in the targeted chemotherapeutic group were xerosis seen in 22 (64.7%) patients, nail changes in 17 (50%), alopecia in 15 (44.1%), and pruritus in 13 (38.2%). CONCLUSIONS: The most common cutaneous side-effects were less prevalent in the patient group using targeted chemotherapeutic agents than in the classic group. Various side-effects associated with chemotherapeutic use which had not been previously reported were also identified in this study. Classic chemotherapeutic agents caused more serious side-effects requiring discontinuation of treatment than targeted chemotherapeutic agents. |
format | Online Article Text |
id | pubmed-8802962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-88029622022-02-04 Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients Utlu, Zeynep Bilen, Handan Postepy Dermatol Alergol Original Paper INTRODUCTION: Side-effects are frequently encountered in classic chemotherapy. However, the recent development of targeted treatments has resulted in a diminution of these. The most common side-effects are dermatological. AIM: To investigate cutaneous changes occurring in patients using classic and targeted chemotherapeutic agents, and the prevalence of these changes in the two groups. MATERIAL AND METHODS: One hundred twenty-eight volunteer oncological patients using chemotherapeutic agents were included in this prospective study. Two subgroups were established, patients using classic and those using targeted chemotherapeutic agents. RESULTS: Xerosis was the most common side-effect, being seen in 93 (72.7%) of the 128 patients. Other common side-effects included alopecia, pruritus, mucositis, skin pigmentation, and palmar-plantar erythema. The most common side-effects in the classic chemotherapeutic group were xerosis seen in 71 (75.5%) patients, pruritus in 50 (53.2%), alopecia in 49 (52.1%), and nail changes in 43 (45.7%). The most common side-effects in the targeted chemotherapeutic group were xerosis seen in 22 (64.7%) patients, nail changes in 17 (50%), alopecia in 15 (44.1%), and pruritus in 13 (38.2%). CONCLUSIONS: The most common cutaneous side-effects were less prevalent in the patient group using targeted chemotherapeutic agents than in the classic group. Various side-effects associated with chemotherapeutic use which had not been previously reported were also identified in this study. Classic chemotherapeutic agents caused more serious side-effects requiring discontinuation of treatment than targeted chemotherapeutic agents. Termedia Publishing House 2021-10-22 2021-12 /pmc/articles/PMC8802962/ /pubmed/35126018 http://dx.doi.org/10.5114/ada.2020.99943 Text en Copyright: © 2021 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Utlu, Zeynep Bilen, Handan Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title | Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title_full | Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title_fullStr | Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title_full_unstemmed | Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title_short | Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
title_sort | evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802962/ https://www.ncbi.nlm.nih.gov/pubmed/35126018 http://dx.doi.org/10.5114/ada.2020.99943 |
work_keys_str_mv | AT utluzeynep evaluationofcutaneoussideeffectsassociatedwithchemotherapeuticuseinoncologicalpatients AT bilenhandan evaluationofcutaneoussideeffectsassociatedwithchemotherapeuticuseinoncologicalpatients |